Pfizer (NYSE:PFE) Rating Increased to Buy at Wall Street Zen

Posted by George Bondi on Aug 2nd, 2026

Wall Street Zen upgraded shares of Pfizer (NYSE:PFE – Free Report) from a hold rating to a buy rating in a research note published on Saturday morning.

A number of other brokerages have also recently weighed in on PFE. Citigroup upped their price target on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. BMO Capital Markets reduced their price objective on Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. Royal Bank Of Canada raised Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price for the company in a research report on Tuesday, June 9th. Morgan Stanley increased their target price on Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $28.50.

Check Out Our Latest Stock Report on Pfizer

Pfizer Stock Up 0.8%

PFE opened at $25.10 on Friday. Pfizer has a 1 year low of $23.11 and a 1 year high of $28.75. The firm has a 50 day moving average price of $25.04 and a 200 day moving average price of $26.15. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The company has a market cap of $143.06 billion, a PE ratio of 19.16 and a beta of 0.35.

Pfizer (NYSE:PFE – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The company had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. During the same period in the previous year, the firm earned $0.92 earnings per share. Pfizer’s revenue for the quarter was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts expect that Pfizer will post 2.96 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Vanguard Group Inc. increased its stake in shares of Pfizer by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock worth $13,479,520,000 after buying an additional 7,031,162 shares during the last quarter. KBC Group NV boosted its stake in Pfizer by 8.3% during the 4th quarter. KBC Group NV now owns 9,193,713 shares of the biopharmaceutical company’s stock valued at $228,924,000 after acquiring an additional 706,426 shares during the last quarter. North Dakota State Investment Board acquired a new position in Pfizer during the 4th quarter worth $5,348,000. PFA Pension Forsikringsaktieselskab bought a new stake in shares of Pfizer in the 4th quarter worth about $76,833,000. Finally, John G Ullman & Associates Inc. increased its position in shares of Pfizer by 35.0% in the 4th quarter. John G Ullman & Associates Inc. now owns 206,065 shares of the biopharmaceutical company’s stock worth $5,131,000 after purchasing an additional 53,467 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Positive Phase 3 vitiligo data: Pfizer reported that oral LITFULO significantly improved skin repigmentation in two late-stage trials for nonsegmental vitiligo. The results support planned regulatory filings and could create a new growth opportunity for the company. Reuters LITFULO vitiligo trial article
Positive Sentiment: Updated COVID vaccine approved in Europe: The European Commission authorized Pfizer and BioNTech’s XFG-adapted vaccine for the 2026–2027 season across the European Union. The approval enables production and advance supply, although seasonal COVID demand remains difficult to forecast. EU approval article
Positive Sentiment: Value appeal and estimates: Investor commentary highlights Pfizer’s roughly 6.8% dividend yield and inexpensive earnings valuation, while Erste Group reportedly raised its FY2027 EPS estimate. These factors may attract income and value-focused investors. Pfizer valuation article
Neutral Sentiment: Upcoming earnings focus: Analysts are watching Pfizer’s second-quarter revenue, adjusted earnings, product sales and full-year outlook. The available reports are previews rather than an announcement of actual quarterly results, so earnings remain a near-term catalyst. Pfizer Q2 earnings preview
Negative Sentiment: Growth concerns remain: Pfizer’s valuation reflects investor skepticism about post-pandemic revenue, a comparatively modest growth profile and execution risks surrounding its pipeline. Its obesity-drug candidate is promising but still late-stage and faces powerful competition from Eli Lilly and Novo Nordisk, limiting any immediate earnings benefit. Pfizer earnings preview and valuation article

Pfizer Company Profile

(Get Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.